Nice graphic presentation of the results! Dr. Katie Liao and her group present the characteristics and disease manifestations of Ro+ #SLE patients from the Australian #lupus registry and biobank @RheumNow #ACR21 abs0323 https://t.co/Yl5sZgiTw1

ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA. Of course it does. Like all these studies, really not sure what this is telling us. Abstr#0455 #ACR21 @RheumNow https://t.co/yNVVZFBWDq

Is it time to consider targeting gut microbiome for treatment of AS? Large study identified: ⭐️Ruminococcus torques associated with FUT2 gene influences risk of developing AS Abs#0068 https://t.co/E1hL18KZbQ #ACR21 #ACRBest @RheumNow

• Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Random…

#ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7

• Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities…

Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte ratio (PLR) along w/ PROs may be helpful to measure dz activity clinically. More studies needed for proof of concept. Abs 0384 #ACR21 #RheumNow @RheumNow https://t.co/ZXyQHNzqz7 https://t.co/va5fBR9Gnk

• A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in …

#ACR21 @RheumNow Abst#0370 by Afinogenova et al. 138 PCP surveyed on Chronic back pain evaluation ▶️58% rarely assess for IBP ▶️40% not comfortable diagnosing AS ▶️70% not comfortable diagnosing axSpA Contributing to a lack of referral to rheumatology and delay in diagnosis.

Annual age-standardized mortality rate (ASMR) improved from 1999-2015, then worsened 2015-2019: #ACR21 Abst#0454 @RheumNow https://t.co/mu1xIO7YlI

Race/ethnicity and residence were independent risk factors for LN mortality which was higher in: ➡️Black patients ➡️Those living in central metro areas #ACR21 Abst#0454 @RheumNow

Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE

• Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop …

Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf

#ACR21 Abst#0456. Fxnal connectivity, ⬆️ blood-brain barrier (BBB) leakage & cognitive impairment (CI) in SLE ⭐️SLE pts ⬆️♀️, older, caucasian, ⬇️ edu than controls ⭐️CI in longer disease, APS ▶️ SLE CI:⬇️Brain-wide connections, BBB permeability https://t.co/fen9OYhWhC @Rheumnow https://t.co/DMQfWCqUhh

• https://bit.ly/3wlgGH3

RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy

• Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…

Serum IL-22 levels elevated in axSpA pts in Israeli study. Possible independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers? Possible target for treatment? Further studies needed. Abs 0385 #ACR21 #RheumNow @RheumNow https://t.co/AUwZFJTlnq https://t.co/WSZ2WjW45W

• The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial…

Can we stop RA developing? Not previously. Double-blind RCT: - arthralgias+ACPA+MRI changes - but no clinical synovitis - abatacept for 6m didn't progress to arthritis: 92% v 65% improvement in MRI: 61% v 31% + benefit to 18m not shown "provocative"! #ACR21 ABST0455 @RheumNow https://t.co/TGxCBhk4r9

New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC

• Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, …